HIV protease inhibitors were introduced into clinical practice over 7 years ago
The introduction of HIV protease inhibitor (PI) proved mortality and morbidity. [1] However, longtherapy into clinical practice in 1996 represented a -term PI treatment has been associated with adverse significant step forward in the treatment of HIV metabolic effects that were recognised as novel toxinfection. The ability of highly active antiretroviral icity syndromes in 1997 and 1998, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and which therapy (HAART) regimens incorporating PI drugs continue to be studied intensively in 2003. These to profoundly suppress viral replication has trans-complications provide significant challenges to formed HIV infection into a manageable chronic clinicians caring for HIV-infected patients, who disease in many patients, and has dramatically im-may be concerned that a mastery of the intricacies of metabolism has to be added to the virology, immu-PIs. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Altered lipoproteins, mimicking the 'athernology and pharmacology knowledge that is already ogenic' profile seen in dyslipidaemic patients with required to practice effectively in this field. How-diabetes mellitus were also documented in PI-treatever, progress has been made in elucidating the ed patients and were shown to precede body habitus pathogenesis of PI-associated metabolic complica-changes in some patients. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Insulin resistance tions, which in turn provides a foundation for a and diabetes developed de novo or worsened in rational approach to clinical management. Addition-patients (with and without morphological change), ally, for those with an interest in human endocrinol-coincident with starting therapy with a PI. [19, 24, [31] [32] [33] [34] [35] [36] ogy and metabolism but who are not HIV clinicians,
The first systematic study that attempted to prothere are significant opportunities to learn from this vide a unifying definition and description of the 'natural experiment '. syndrome in a large Australian cohort suggested that In this review, evidence for causal associations subcutaneous fat wasting in the face, limbs, buttocks between PI therapy and metabolic abnormalities is and upper trunk (termed 'peripheral lipodystrophy') presented within the context of the 'lipodystrophy was associated with abdominal visceral obesity, syndrome', with particular emphasis on the patho-dyslipidaemia and insulin resistance in HIV-infectphysiology of insulin resistance and triglyceride-ed patients. [37] The vast majority of affected patients rich dyslipidaemia. The clinical implications of were receiving PI-containing HAART. The facts these metabolic complications are then addressed, that morphological and metabolic changes appeared focusing specifically on cardiovascular disease risk, to aggregate at a population level, their phenotypic and the importance of individualising clinical man-similarity to the 'metabolic syndrome' (see table I) agement to incorporate potentially modifiable host-and the plausibility of PIs as a unifying cause, all and disease-related factors. Current approaches to helped drive the view that these changes formed a the management of metabolic complications, new single 'lipodystrophy syndrome' [37] [38] [39] (figure through interventions such as 'switching' antiretro-1). viral regimens or the use of adjunctive treatments
Since that time evidence has emerged that subcu-(e.g. lipid-lowering and/or insulin-sensitising taneous fat wasting behaves as an independent or drugs), are also explored. This area has also been the partially independent process, while visceral fat acsubject of a recent review from an International cumulation, dyslipidaemia and insulin resistance ap-AIDS Society -USA panel, [18] which includes pre-pear to be closely linked (figure 2). Clinical trials liminary recommendations for management.
have demonstrated that the severity of subcutaneous fat wasting is primarily determined by choice (and
HIV Protease Inhibitor (PI) Therapy and the 'Lipodystrophy Syndrome'
Historically, the use of the term 'lipodystrophy syndrome' originates in two reports, published in late 1997 [2] and early 1998, [3] describing wasting of subcutaneous fat in the face and limbs of HIVinfected patients treated with the PI indinavir, reminiscent of rare congenital and acquired lipodystrophy syndromes. From late 1997 onwards, others described benign symmetric lipomatoses, localised lipomas, 'buffalo humps', intra-abdominal fat accumulation and breast enlargement in HIV-infected men and women on various antiretroviral combinations, predominantly (but not exclusively) including a Note that an alternative definition of the metabolic syndrome has also been proposed by the World Health Organization (see Ford and Giles [40] ). The definition provided in this table has been incorporated into National Cholesterol Education Program (NCEP) guidelines. duration) of nucleoside reverse transcriptase inhibi-cluster at a population level, suggesting that they are tor (NRTI) therapy, particularly stavudine, [42] [43] [44] [45] related outcomes. [47, 48] This is also observed in the while the use of PI therapy does not have a signif-setting of HIV PI therapy. Hence, elucidating the icant impact on this outcome. Data from switching molecular pathophysiology of PI-induced metabolic studies also support this assertion, in that substitut-dysregulation may help to unravel the complex bioing an alternative NRTI for stavudine (in 94% of logical relationships between fatty acid and glucose cases presented to date) has been associated with metabolism, [49] an area of research of particular curimprovement in fat wasting, while more than 30 rent interest as prevalence of the metabolic synclinical trials investigating PI switching have shown drome and diabetes reach epidemic proportions in no beneficial effects (reviewed by Dreschler and the general community. [47] [48] [49] While the direct contriPowderly [46] ). However, as will be discussed further, bution of HIV PI therapy is the focus of this discusdiscontinuing PI therapy has been associated with sion initially, it must be borne in mind that the improved metabolic outcomes [46] and there is strong metabolic effects of HIV infection itself can signifievidence that PIs are causally linked to components cantly influence the relationship between these of the 'metabolic syndrome', incorporating insulin drugs and their metabolic consequences, as will be resistance, triglyceride-rich dyslipoproteinaemia discussed further. and abdominal/visceral obesity.
PI Therapy and Dyslipidaemia

HIV PI Therapy and the
Dyslipidaemia associated with PI therapy is cha-'Metabolic Syndrome ' racterised by increased levels of triglyceride and It is notable that insulin resistance, triglyceride-triglyceride-rich lipoproteins (figure 3). These lipid rich dyslipoproteinaemia and abdominal obesity fractions are normally elevated in the post-prandial sue and liver, increased lipolysis, and markedly decreased clearance of triglyceride-enriched VLDL and chylomicrons.
This metabolic phenotype is typical of defective post-prandial lipid metabolism. Indeed, in a recent study Merwood and colleagues [58] have demonstrated significantly increased post-prandial triglyceride, and IDL, large VLDL, small LDL and small HDL cholesterol in PI-treated patients (n = 23) compared with those receiving non-PI-containing HAART (n = 16). This group has also shown that endothelial dysfunction is associated with this metabolic cluster in PI-treated patients,
[59] consistent with population-based studies showing that elevated levels of triglyceride-enriched lipoproteins are independently predictive of cardiovascular disease. [60, 61] Insulin plays a critical role in coordinating the post-prandial metabolic response, in which carbohydrates are utilised as the primary source of fuel for oxidative reactions while fatty acids are directed into adipose stores and converted to triglyceride. This energy store can then be called upon when metabolism must rely more heavily on fatty acids as phase, and are destined for delipidation in the peria fuel source in the postabsorptive or 'fasted' state. pheral circulation by the action of endothelial lipoHence, increasing insulin levels after food intake protein lipase so that fatty acids may be removed to normally increase fatty acid uptake and triglyceride adipose tissue and stored (after conversion to trigsynthesis within adipocytes, and inhibit lipolysis lyceride). In PI-associated dyslipidaemia, elevated (free fatty acid release from triglyceride) from adiplasma triglyceride levels are typically accompanied pose stores. Dysregulation of this response so that by increased total, very low density lipoprotein lipolysis is not suppressed in the post-prandial phase (VLDL) and intermediate density lipoprotein (IDL) leads to inappropriate fatty acid flux and is a procholesterol, apolipoproteins B, CIII and E, small-posed mechanism for increased levels of triglycerdense low density lipoprotein (LDL) cholesterol, ide-enriched lipoproteins. Dysregulated/increased and increased small high density lipoprotein (HDL) lipolysis has been demonstrated in the setting of PI cholesterol. [29, [50] [51] [52] [53] These lipid changes are com-therapy by Hadigan et al., [62] who noted that lipolymonly accompanied by elevated insulin levels and sis rates independently predicted insulin resistance increased levels of free fatty acid have also been (p = 0.03). Interestingly, this group went on to observed. [53] [54] [55] Dysregulated fatty acid metabolism demonstrate that acute inhibition of lipolysis has been documented in a study by Sekhar and through the use of acipimox 1000mg in two divided colleagues, [56] who used stable isotope tracer tech-doses in seven insulin-resistant PI-treated patients niques to provide a comprehensive assessment of in produced a significant decrease in insulin resistance vivo lipid metabolism dynamics in patients receiv-(p = 0.01). [63] These results cannot be generalised ing PI-based HAART. [56] Turnover of fatty acids from this small and highly selected study, and it was found to be dramatically increased, with elevat-must also be recognised that acipimox treatment did not fully restore insulin sensitivity in these patients. ed fat oxidation and re-esterification in adipose tis-Nevertheless, these findings raise the possibility that led study in which insulin sensitivity was assessed the excessive liberation of fatty acids from adipose by euglycaemic hyperinsulinaemic clamp testing. [64] tissue may play a significant role in determining Hence, insulin resistance can be rapidly induced by both insulin resistance and dyslipidaemia in patients PI therapy and is not necessarily secondary to receiving PI therapy. changes in fat distribution (i.e. subcutaneous fat wasting or visceral fat accumulation). The use of 2.2 PI Therapy and Insulin Resistance healthy subjects indicates that neither HIV infection nor concurrent NRTI therapy is required for these There is now strong evidence from in vivo studies effects. in both HIV-infected and seronegative individuals Other studies that have accurately assessed insuthat PI therapy is independently associated with lin sensitivity in vivo, through the use of hyperinsuinsulin resistance. Probably the most compelling linaemic euglycaemic clamp [55, 65, 66] or intravenous data among a number of recently published studies glucose tolerance test with frequent sampling of has shown that a single dose of indinavir 1200mg plasma glucose and insulin, [67, 68] have consistently was sufficient to induce a significant reduction in demonstrated significant insulin resistance with deinsulin sensitivity (average decrease 34%, p < creased insulin-stimulated oxidative and non-oxida-0.001) in six healthy controls in a placebo-control- Insulin resistance decreases delipidation of chylomicrons (derived from dietary fat) and VLDL-C (from hepatic processing of fatty acids) at the level of lipoprotein lipase, which is produced and secreted by adipocytes in response to insulin. Increased lipolysis from adipocytes, as well as increased chylomicron remnants, increase hepatic processing to produce VLDL-C. VLDL metabolism normally produces LDL that is then readily cleared by LDL receptors. However, 'altered', triglyceride-enriched VLDL is diverted towards the production of IDL from HDL, as well as small, dense LDL that is less effectively cleared via the LDL receptor and is more susceptible to oxidative modification (adapted from Nolan et al., [57] with permission). Apo B100 = apolipoprotein B100; B48 = apolipoprotein B48; CETP = cholesterol ester transfer protein; FFA = free fatty acid; HDL = high-density lipoprotein; IDL = intermediate density lipoprotein; LCAT = lecithin:cholesterol acyltransferase; LDL = low-density lipoprotein; LPL = lipoprotein lipase; TG = triglyceride; VLDL = very low-density lipoprotein; VLDL-C = VLDL cholesterol. There are a number of potential confounding vir, ritonavir, saquinavir and lopinavir, although it is factors that need to be considered when examining not possible to differentiate effects of specific drugs.
relationships between HIV PI therapy, metabolic These data suggest that a number of insulin-responcomplications and body composition abnormalities. sive tissues are involved in this aberrant response.
These factors, along with a paucity of longitudinal For example, fasting plasma free fatty acids are data, have combined to ensure that the role of viscerderived solely from adipose tissue; the liver is the al/abdominal fat accumulation within the 'lipodysmajor organ responsible for endogenous glucose trophy syndrome' remains relatively poorly underproduction; and skeletal muscle is the most signif-stood. First, it remains unclear if PI therapy contribicant site of insulin-stimulated glucose uptake and utes to visceral adipose tissue accumulation oxidation.
independent of its effects on lipid/glucose metabol-A recent study has also examined lipid accumula-ism. Current evidence suggests that insulin resistion within skeletal myocytes using magnetic spec-tance is the dominant risk factor for visceral adipositroscopy, finding strong correlations between the ty, as a number of studies have demonstrated that severity of insulin resistance and the presence of patients with the 'mixed lipodystrophy syndrome' intracellular lipid in soleus muscle (correlation of (i.e. those with lipoatrophy as well as visceral adiclamp glucose infusion rate and soleus intramyocel-posity) have more prominent insulin resistance compared with patients with lipoatrophy alone. [51, 54, 71] lular lipid, r = -0.71, p = 0.0005). [65] Intrahepatic
The rapidity of onset of PI-associated metabolic lipid detected by magnetic resonance imaging has complications in the absence of body composition also been observed in insulin resistant PI-treated changes [64, 72, 73] also argues that increased visceral patients. [69] These results are in agreement with fat is a consequence of dysregulated insulin metaBehrens et al., [66] who propose that elevated tissue bolism and post-prandial lipid metabolism, rather levels of free fatty acids provides a unifying mechathan its cause. nism explaining their observation that skeletal Secondly, the prevalence of abdominal obesity in muscle insulin-stimulated glucose transport and the developed world is rapidly increasing (with agephosphorylation is markedly impaired (~50%) adjusted estimates of 38.6% among US adults, rangamong PI-treated patients compared with therapying from 23% and 30.5% for African-American and naive HIV-infected patients. Grinspoon and colWhite males, respectively, to 62% and 43.5% for leagues [70] have also demonstrated that elevated fastAfrican-American and White females, respectiveing free fatty acid levels are strong independent ly). [47] In this context, so-called 'lifestyle factors' predictors of insulin resistance (measured as insulin such as dietary fat intake and amount of exercise, response to oral glucose challenge) [p = 0.03], conalong with increasing age, are likely to be important trolling for age, gender and body mass index and risk factors in the general population as well as body composition (n = 64). [70] This proposed mech-among PI-treated patients. The high rate of abdomianism of insulin resistance is in accordance with nal obesity among developed societies, [47] and the current concepts, which give a prominent pathogen-high degree of variability in objectively measured ic role to fatty acid dysregulation at the cellular visceral fat area in these populations, [74] may also level. [49] make it difficult to use this endpoint as a means of Hence, there is compelling evidence from in vivo discriminating 'cases' and 'controls' in cross-secstudies that PI-induced insulin resistance and trig-tional analyses. lyceride-rich dyslipidaemia have a common associaIt has been argued in a study by Mynarcik and tion with dysregulated fatty acid metabolism.
colleagues [75] that lipoatrophy itself may contribute to risk of insulin resistance. However, no correlation liver that plays a critical role in inducing the signabetween insulin resistance and limb fat was docu-ture adipocyte response to post-prandial insulin remented among the lipodystrophic patients in this lease. [78] [79] [80] In adipocytes it is involved (either directstudy, although diminished ability of insulin to sup-ly or via downstream stimulation of peroxisome press free fatty acid levels (i.e. to inhibit lipolysis proliferator activated receptor gamma [PPAR-γ]) in from adipose tissue) was highly correlated with in-increasing fatty acid uptake (via lipoprotein lipase) sulin resistance in this group (r = 0.56, p < 0.001). [75] and fatty acid synthesis from carbohydrate precurOther studies have shown powerful associations be-sors (via fatty acid synthase), inhibiting lipolysis tween visceral fat area and insulin resistance inde-(via hormone sensitive lipase), increasing adipocyte pendent of lipoatrophy, [65, 67] in keeping with clinical differentiation, and increasing uptake and utilisation data that patients with 'pure lipoatrophy' have rela-of glucose as an energy substrate (via insulin-sensitively preserved insulin sensitivity.
tive glucose transporter 4 [GLUT4], glucokinase) Once established, does visceral adiposity re-[ figure 4 ]. [78] [79] [80] Caron et al. [81] and Bastard and present an independent risk factor for sustained met-colleagues [82] have provided elegant studies indicatabolic abnormalities? Data presented recently by Dr ing that PI therapy inhibits the translocation of acPeter Reiss [76] in a plenary presentation at the 10th tive SREBP-1c from endoplasmic reticulum and Conference on Retroviruses and Opportunistic In-nuclear membranes to the nucleus. They also defections, Boston, USA, suggest that this is the case. tected altered electrophoretic mobility of activated For example, in the Spanish Nevirapine, Efavirenz, SREBP-1, suggesting abnormal processing or phosAbacavir (NEFA) study (involving switching PI phorylation of active SREBP-1 after proteolytic actherapy to non-NRTI [NNRTI]), the metabolic ben-tivation from its 125 kDa precursor form. Other efits of PI switching therapy were greatly reduced in studies corroborate these results in vitro, [83] [84] [85] indipatients with pre-existing body composition cating that pharmacological doses of PI drugs may changes. [77] directly induce insulin resistance in adipocytes, as To conclude, visceral fat accumulation is certain-well as a defect in the late stages of adipocyte ly associated with the use of HIV PI therapy. How-maturation characterised by decreased expression of ever, current evidence suggests that this component nuclear transcription factors CCAAT-enhancer of the 'lipodystrophy syndrome' may best be conbinding protein (C/EBP)-α and PPAR-γ. [83] [84] [85] Intersidered as a downstream effect of the metabolic estingly, defective SREBP processing may also be effects of PI drugs.
central to the pathogenesis of Dunnigan-type familial partial lipodystrophy, a severe monogenic form of
Potential Mechanisms of PI-Associated insulin resistant lipodystrophy that resembles
Metabolic Complications
HAART-associated lipodystrophy phenotypicalThree mechanisms by which PI therapy may ly. [86] The underlying genetic defect in this condition initiate insulin resistance and dyslipidaemia are sup-involves mutations in the LMNA gene that encodes ported by in vitro studies, and are indirectly sup-nuclear lamin A, a protein involved in the organisaported by clinical data. It should be noted that these tion of the nuclear membrane and the regulation of pathophysiological mechanisms may well be over-trafficking of transcription factors into the nucleus. lapping, and are not mutually exclusive (figure 4).
It has been proposed that mutated LMNA products may interact abnormally with SREBP, so that acti-
Defective Activation and Nuclear
vation of nuclear transcription factors is impaired [86] Translocation of the Transcription Factor Sterol (see figure 4) . In vitro (using 3T3-F442A mouse
Regulatory Element-Binding Protein 1 adipocyte cell lines), a hierarchy of PI effects has Sterol regulatory element-binding protein been suggested, with half-maximal effective con-(SREBP) is an endoplasmic reticulum-derived transcription factor common to adipose tissue and the centrations (EC50) on insulin signalling pathways of 
Proteasomal Inhibition
16 μmol/L (indinavir), 25 μmol/L (nelfinavir) and Unlike other HIV-1 PIs, ritonavir appears to have >100 μmol/L (amprenavir). [87] activity as a proteasome inhibitor at pharmacological doses [92] and shows specificity for a proteasomal
Direct, Reversible Inhibition of Insulin-Sensitive Glucose Transporter-4
pathway involved in the degradation of Murata et al. [88] [89] [90] have demonstrated reversible SREBP-1.
[93] Accordingly, ritonavir appears to ininhibition of GLUT4 induced by a number of PI crease hepatic triglyceride production via increased drugs, most notably by indinavir. In primary rat stabilisation of nuclear SREBP-1c.
[94] Research by adipocytes, indinavir rapidly inhibited glucose up-Distler and colleagues [95] is also in keeping with this take at pharmacologically relevant concentrations mechanism, in which there is increased hepatic sen-(inhibition constant [Ki] ~10 μmol/L), while de-sitivity to fatty acid stimulus, leading to increased creased insulin sensitivity was also seen in rats VLDL and apolipoprotein B production and secreacutely exposed to indinavir 15 mg/kg that reversed tion. within 4 hours of ceasing indinavir infusion. These data suggest that PI drugs interact directly with the 2.5 Differentiating the Effects of Specific PI insulin-responsive glucose transporter at the cell Drugs on Metabolic Outcomes surface of adipocytes and skeletal muscle cells. This observation has also been confirmed by Ben-RomaTaken together, these mechanisms provide a no and colleagues, [91] who have elegantly demon-possible explanation for clinically observed differstrated that translocation of GLUT4 is unaffected.
ences in metabolic outcomes associated with specif-ic PI drugs. For example, ritonavir is notable within ide levels (~40 mg/dL) and no significant effects on total, LDL or HDL cholesterol. Similarly, among 31 the PI class for its ability to induce hypertriglycerheavily pretreated patients commencing salvage idaemia, [30] and its use was associated with marked therapy with ritonavir-boosted amprenavir (600mg), elevations of triglyceride and apolipoprotein B no significant increases in total cholesterol (p = 0.8) levels in HIV-negative individuals over a 2-week or triglyceride (p = 0.4) were observed over 16 period. [72] This effect may be attributed to its specifweeks. In 13 patients with elevated cholesterol ic ability to increase hepatic triglyceride production levels at baseline (>200 mg/dL [>5.2 mmol/L]), secondary to its activating effects on SREBP-depentotal cholesterol decreased significantly (median dent lipid metabolism in the liver. Similar results difference 33 mg/dL [0.85 mmol/L], p = 0.029); have been obtained in ten healthy volunteers treated with a similar effect observed in eight patients with with lopinavir 400mg/ritonavir 100mg twice daily baseline triglyceride levels >200 mg/mL (median for 4 weeks, in whom fasting triglyceride levels rose difference in triglyceride 82 mg/mL [2.1 mmol/L], p significantly while insulin sensitivity remained = 0.001).
[101] stable, as measured by euglycaemic, hyperinsuFurther research is required to establish the metalinaemic clamp. [73] On the other hand, indinavir bolic profile of these drugs in large numbers of HIVtherapy in HIV-negative individuals is associated infected patients, as current data are generally limitwith acute induction of insulin resistance, [64, 96] aled to 48 weeks. As these HIV PIs enter routine though triglyceride-rich dyslipidaemia was not obclinical practice, these long-term results are awaited served in the initial 4 weeks of therapy. [96] This with interest. suggests that the acute inhibition of insulin-stimulated glucose transport (via GLUT4), which is most potently induced by indinavir, [88] may be the prima-3. Clinical Relevance of PI-Associated ry mechanism in the early stages of therapy.
Metabolic Complications
Following from these observations, preliminary studies involving the more recently introduced PI While the pathophysiology of metabolic abnordrugs, atazanavir and amprenavir, suggest that they malities associated with PI therapy has so far been are relatively benign. In one study (BMS the dominant focus of this review, the clinical rele-AI424-044), [97] 'intraclass' PI switching from nelfi-vance of these adverse effects and the pertinent navir to atazanavir therapy was associated with de-factors that require consideration in managing these creased total and LDL cholesterol (-16% and -21%, complications in clinical practice need to be considrespectively), and decreased triglycerides (-28%) [p ered. The clinical implications of PI-induced metabolic syndromes may be distilled as a number of < 0.001] to levels comparable with baseline values questions. obtained prior to nelfinavir introduction. This is in keeping with in vitro studies in which atazanavir • What is the most appropriate method of testing performed well in comparison with other HIV PIs [98] for these complications and when should these (although amprenavir was not included in these tests be performed?
analyses). Regarding amprenavir, prospective eval-• Are these metabolic complications associated uation of metabolic outcomes in patients commencwith increased morbidity or mortality within a ing therapy has shown no evidence of insulin resistimeframe that is relevant to HIV-infected patance associated with this drug to 48 weeks. [99] Antients? In particular, will the benefits of effective other study comparing the effects of ritonavir-HIV therapy be offset by increased risk of cardiovascular disease and/or diabetes? boosted amprenavir (600 or 900mg) with either efavirenz or tenofovir over 24 weeks [100] indicate that • What are the most appropriate treatment stratethe tenofovir plus amprenavir regimen (n = 60) is gies in cases where metabolic complications are associated with only a modest increase in triglycerestablished? (SMART, involving ART-experienced patients; and The ideal time to first assess the metabolic status FIRST, in which patients are ART naive at baseof a patient is before the introduction of HIV PI line), and comparing these with US populationtherapy. There are a number of reasons for this. based data (the Multiple Risk Factor Intervention First, in any patient a 'baseline' measure of metabol-Trial [MRFIT] and the National Health and Nutriic status provides a reference point that allows a tion Examination Survey [NHANES]), he noted that more informed interpretation of any subsequent ef-levels of total cholesterol in heavily ART-treated fects of therapy. Secondly, this approach allows the men involved in the SMART study were comidentification of underlying metabolic abnormalities parable with age-matched men from the general that may independently increase cardiovascular risk population, while levels were significantly lower in and which may alter decisions about choice of anti-ART-naive patients from the FIRST study. This is in retroviral therapy (ART) regimen. It must be keeping with research showing that advancing HIV remembered that the prevalence of the metabolic infection is associated with decreased levels of total, syndrome (defined in table I) is high in the general HDL and LDL cholesterol, while triglyceride levels community (~30% according to a large population-are associated with progression to AIDS. [106] Therebased US study [47] ) and is also age-dependent, rising fore, the effects of PI therapy on metabolic parasteeply in both males and females aged >40 years. meters need to be placed into the context of the There is also an appreciable prevalence of genetical-baseline value, determined by the patient's HIV ly determined dyslipidaemia (~1% with familial status as well as other factors (e.g. genetic predispocombined hyperlipidaemia, 0.2% with familial sition to hypercholesterolaemia). A 'change in total hypercholesterolaemia) [102] and of diabetes cholesterol' associated with PI therapy that restores (4-5%). [103] It would be predicted that these diseases cholesterol levels to normal, is unlikely to have the may be exacerbated by PI therapy; therefore, early same impact on cardiovascular risk as an elevation recognition is important. It is also critical that modi-of cholesterol from normal to pathological levels. fiable factors (e.g. smoking, hypertension, sedentary Otherwise, recent guidelines recommend that lifestyle and obesity) are identified and incorporated fasting glucose and lipid assessment should be perinto an overall assessment of cardiovascular risk. formed prior to commencing or switching of a new This is especially true of smoking, which remains a ART regimen, and should then be repeated 3-6 highly prevalent cardiovascular risk factor among months later and at least annually in patients who HIV-infected individuals. Global cardiovascular remain on stable therapy. [18] risk, and the contribution of modifiable risk factors, may be calculated using available algorithms (e.g.
What Tests Should be Performed?
Framingham risk equations and US National Cho-
The choice of tests needs to be predicated on lesterol Education Program [NCEP] III risk calcula-providing information that can be used to determine tor; [104] a New Zealand-based calculator is also high-cardiovascular risk, and which may guide intervenly recommended [105] ).
tions. The minimum lipid evaluation should include This approach of obtaining a baseline assessment a fasting measurement of triglyceride, and total, also allows for the identification of metabolic effects HDL and LDL cholesterol. From these parameters, of HIV infection itself, which may be significant. In the 'non-HDL' cholesterol fraction provides an estia plenary talk at the recent 4th International Work-mate of triglyceride-rich lipoproteins. This measure shop on Adverse Drug Reactions and Lipodystrophy has been incorporated into recent NCEP guidelines that stress the importance of recognising and diag-while receiving HAART [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] have now given way nosing the metabolic syndrome. [41] This may be to larger cohort and population-based studies of particularly valuable in PI-treated patients as an cardiovascular disease among HAART recipiassessment tool and therapeutic guide. Where it is ents. [117] [118] [119] [120] [121] Results have been conflicting, with eviavailable, measurement of apolipoprotein B can also dence both for [117] [118] [119] and against [120, 121] increased provide a useful marker of the number of atherogen-incidence of cardiovascular disease among PI recipic lipoparticles present, which can help to differ-ients. However, some discernible patterns are entiate atherogenic hypertriglyceridaemic states emerging. The first is that traditional cardiovascular from those that are more benign. [61] Diabetes should risk factors (i.e. smoking, hypertension) remain imalso be excluded with fasting glucose assessment; portant predictors of overt vascular disease, sugideally, with incorporation of an oral glucose toler-gesting that the metabolic complications of PI therance test to identify those with impaired glucose apy may hasten the progression of vascular disease tolerance. While insulin resistance appears to be a in those who are already predisposed. The second is common problem among PI-treated patients, this is that cardiovascular risk may be decreased in patients difficult to assess accurately in clinical practice and who have not commenced ART and who have unat this time does not warrant specific therapeutic controlled HIV infection. [120] As mentioned in secintervention if diabetes is not present. Again, recent tion 3.1, advancing HIV disease and immune defiguidelines offer a very practical and reasonable ap-ciency is accompanied by changes in lipoprotein proach to assessment and monitoring in this set-metabolism characterised by decreased levels of ting. [18] total, LDL and HDL cholesterol, as well as decreased apolipoprotein B. [106] Progression to AIDS
HIV PI Therapy and Cardiovascular Risk
is associated with elevated triglyceride levels, [122] while the other metabolic parameters fall in parallel There is justified concern that the cluster of lipid with CD4+ cell counts. [123] It is also possible that and glucose abnormalities associated with PI ther-HIV-associated loss of cell-mediated immune funcapy constitutes an atherogenic metabolic profile. tion may limit the progression of atherosclerosis, in How the baseline risk of vascular disease in HIV-keeping with current concepts of atherogenesis as an infected patients compares with the general popula-inflammatory process [124, 125] involving specific Ttion is not clear, nor whether the dyslipidaemia (and cell and macrophage populations. [126] [127] [128] Hence, the immune restoration) induced by HAART increases 'baseline' level of cardiovascular risk prior to the this baseline risk independent of improved survival introduction of PI therapy, which is determined in or improved surveillance. It is also worth considerpart by immunological status, may have a signifing, when attempting to interpret the available data, icant modulating effect. that the progression from the earliest events in the Probably the most direct evidence for an associaatherogenic process to atherosclerotic plaque formation between PI therapy, triglyceride-rich dystion, and finally to the development of overt vasculipidaemia and cardiovascular disease has come lar disease, is one that occurs over years or even from a study of endothelial function in PI-treated decades. Consequently, it should not be expected patients with dyslipidaemia.
[59] Endothelial dysfuncthat studies of 'hard' cardiovascular endpoints, such tion is considered to be an early event in atheras incidence of myocardial infarction and/or death ogenesis, [124] involving loss of the endothelial resattributable to cardiac disease, are likely to discern ponse to ischaemic or mechanical stimuli with an the influence of PI therapy on cardiovascular risk with any precision at this time (i.e. 6 years after the appropriate (nitric oxide-mediated) vasodilatory resintroduction of PI drugs into clinical practice).
ponse. It can be assessed non-invasively by measuring brachial artery flow-mediated dilatation (FMD).
Initial case reports of premature vascular disease
In this study, involving 22 PI-treated and 15 PIin those with dyslipidaemia and/or insulin resistance naive HIV-infected adults, PI therapy was asso-patients with concomitant diabetes who, fortunately, ciated with elevated triglycerides and triglyceride-remain uncommon at present (~2-5%). [30] rich lipoproteins, and these metabolic parameters (chylomicrons, IDL and VLDL cholesterol) were in 4.1 Adjunctive Lipid-Lowering Therapy turn predictive of impaired endothelial function (linThe NCEP guidelines mentioned earlier (see secear regression model R 2 = 67%, p < 0.01). Overall, tion 3.1), [41] which are also summarised in the pub-FMD in the PI-treated group was significantly relished guidelines for management of PI complicaduced compared with the PI-naive group (2.8± 4.6% tions, [18] provide a rational basis for decisions revs 6.1± 6.7% [mean ± SD], p = 0.005). These data garding use of lipid-lowering therapy. A particularly provide evidence for the atherogenic potential of the important aspect of this approach is the assessment PI-associated metabolic phenotype, and identify asof '10-year risk' of cardiovascular disease. Of note, sociations between endothelial dysfunction and spefor patients with a predicted high level of risk cific lipoprotein fractions that have previously been (>20%, representing those with existing vascular shown to determine cardiovascular risk in HIVdisease or diabetes), the recent Heart Protection negative populations with triglyceride-rich dyslipiStudy [134] (n ≈ 20 000) has demonstrated that the use daemia. [60, [129] [130] [131] of HMG-CoA reductase inhibitor (statin) therapy is Two studies have assessed coronary artery morassociated with significant reduction of major vasphology directly using electron beam computed tocular events (~25%) and mortality (~13%) irrespecmography (CT) in 85 patients, of whom ~40% had tive of the severity of hyperlipidaemia when statin significant dyslipidaemia for approximately 24 therapy was initiated. In these patients, simvastatin months. [132, 133] No structural changes were noted in therapy over 5 years was associated with reduction either study, although concurrent positron emission of LDL cholesterol in the order of 1.0 mmol/L (38 tomography scanning suggested the presence of enmg/dL). [134] dothelial dysfunction in the coronary vasculature. This view of the success of lipid-lowering therTaken together, these data suggest that PI therapy apy being measured by effects on vascular outcomes contributes to an atherogenic metabolic profile, and rather than magnitude of cholesterol reduction may that increased cardiovascular risk is likely to manibe particularly relevant in the context of PI-assofest through triglyceride-rich dyslipidaemia and the ciated dyslipidaemia, as trials involving both statins 'metabolic syndrome' phenotype, as recognised in and fibric acid derivatives have had limited impact recent NCEP guidelines. It is important to recognise, on cholesterol and triglyceride levels. however, that other factors may significantly modu-
The efficacy of statins in treating PI-associated late the atherogenic process. These include well dyslipidaemia has been recently investigated by established cardiovascular risk factors, such as Stein et al. [135] (n = 16) and by Doser et al. [136] (n = smoking and hypertension, and in the specific case 16). In both studies, statin therapy produced statistiof the HIV-infected patient, immunological as well cally significant improvements in cholesterol and as metabolic consequences of HIV infection itself.
triglyceride fractions, but the magnitude of the effect observed prompted both investigators to con-4. Approaches to Treatment of clude that benefit was limited. In the first placebo-PI-Associated Metabolic Complications controlled study, using pravastatin 40 mg/day, the atherogenic lipoprotein subfractions specifically afThe fundamental concept in managing the com-fected by PI therapy were identified (increased small plications of PI therapy is that treatment should be LDL and large VLDL cholesterol particle levels, based on the global assessment of cardiovascular and decreased large HDL cholesterol). Compared risk, rather than on the interpretation of individual with these 'baseline' values, pravastatin therapy was parameters. The obvious exception to this rule is in associated with significant reductions in LDL cho-lesterol and small VLDL cholesterol particle levels.
Switching HIV PI Therapy
However, the level of large VLDL particles did not A recent review has summarised the results of change (p = 0.44), nor did average LDL particle size reversibility studies presented or published to date (p = 0.23). In the second study, the use of fluvastatin (2002). [46] If patients and their physicians want to 40 mg/day for 4 weeks resulted in levels of total revise therapy to improve metabolic profiles, then cholesterol <7.0 mmol/L (270 mg/dL) in only 8 of there is evidence that this may occur within a 6-to 16 participants, compared with 6 of 16 at baseline. 12-month period if PIs are replaced with an NNRTI However, total cholesterol decreased from a mean (nevirapine or efavirenz) or with abacavir in triple value of 8.0 mmol/L (SD 0.5) to 6.5 mmol/L (SD NRTI regimens. [46] Interestingly, the NNRTIs nevi-0.4) in the study (p < 0.01), consistent with results rapine and efavirenz have been associated with a seen in the Heart Protection Study. Similar results specific metabolic profile that appears to be antiwere presented in 2001, [137] in which no significant atherogenic. This was most clearly observed in the benefit from lipid-lowering therapy was found (n = Atlantic trial, [141] in which the use of nevirapine was 103, 92% men, 82% receiving PI therapy) over a associated with increased levels of 'large' HDL median of 70 weeks of follow up, with the use of cholesterol. A recent small study (n = 32) comparing statins and fibric acid derivatives according to efavirenz (NNRTI) and nelfinavir (PI) therapy has NCEP guidelines using a stepwise approach (33 also revealed that 16 weeks of PI use preferentially received second regimens and 15 received third increased atherogenic small HDL cholesterol 44.8% regimens). In this study, only 16% of those continu-from baseline, while efavirenz therapy increased ing PI therapy reached target levels of LDL and total large (anti-atherogenic) HDL cholesterol by 41% on cholesterol after >52 weeks. Finally, a randomised average. [142] Importantly, replacing effective PI thertrial (ACTG 5087 [138] ) comparing pravastatin and apy with an NNRTI or NRTI has not been associated fenofibrate therapy for lipid lowering in PI-treated with loss of antiretroviral efficacy. [46] patients with elevated triglyceride and LDL cholesThere may also be a role for intra-class PI switchterol levels has been halted by its data and safety ing, in which atazanavir or amprenavir are intromonitoring board after 12 weeks, as <5% of patients duced in place of another PI drug. As previously responded to either drug alone, with response mea-mentioned in section 2.5, switching from nelfinavir sured as a composite of LDL cholesterol and trig-to atazanavir in the BMS AI424-044 study delyceride reduction. In 136 patients who then creased total and LDL cholesterol as well as trigprogressed to combination therapy (pravastatin plus lyceride to levels comparable with those obtained fenofibrate), response rates remained at ~10%. [138] before the introduction of nelfinavir.
[97] Further studies in this area are awaited. Despite the evidence for limited efficacy of staAlthough the benefit that can be expected from tins and/or fibric acid derivatives, recent data point switching PI therapy is difficult to quantify because to an increasing use of lipid-lowering drugs among of the varying methodology used in switching studpatients receiving PI therapy. In an analysis of a US ies, it appears to be at least comparable with the managed care database [139] (1998-2001, n ≈ 3500 effects seen with statin therapy, particularly in studper year), lipid-lowering therapy was prescribed for ies involving switching to nevirapine and aba-18.4% of PI recipients in 2001, compared with cavir.
[46]
12.2% of non-PI-treated patients and 5.5% of ARTnaive patients in the same period. This prevalence
Recommendations for Preventing and
was higher than in 1998, when 8.7% of PI-treated
Treating Dyslipidaemia patients were treated for dyslipidaemia. [139] A similar analysis, utilising the Californian Medi-Cal dataThe fact that prevalence rates of the metabolic base (1996-2000) also revealed a bias towards treat-syndrome (and of diabetes) are rapidly increasing in ing younger patients, particularly males. [140] developed countries suggests that factors involved in pathogenesis are likely to be modifiable. In partic-receiving PI therapy. Within this context: (i) lipidular, attention to dietary modification and increasing lowering drugs should ideally be prescribed for their energy expenditure through exercise would be pre-therapeutic benefits on cardiovascular disease, as dicted to reduce the risk of metabolic complications determined by global risk assessment; and (ii) failin the setting of PI therapy, as well as to reduce ure to meet therapeutic goal levels should not autocardiovascular risk. [143] Hence, in all patients com-matically lead to the use of combined or intensified mencing HIV PI therapy, interventions that may therapy. Choice of lipid-lowering therapy should be promote these 'lifestyle' changes are likely to have guided by the dyslipidaemic phenotype, with the use substantial benefits. [144, 145] Similarly, modification of fibric acid derivatives when hypertriglycerof traditional cardiovascular risk factors should also idaemia is the dominant manifestation and statins be attempted, with a recognition that these interven-for hyperlipoproteinaemia. Within the statin class tions may have a greater impact on cardiovascular (reviewed in Schambelan et al. [18] ), concomitant use risk than dyslipidaemia itself. of simvastatin or lovastatin with PI therapy should be avoided, as there is increased risk of drug toxicity In patients with an estimated 10-year risk of as a result of PI-associated inhibition of the cytocardiovascular disease >20%, consideration should chrome P450 3A4 metabolic pathway. Atorvastatin be given to switching PI therapy if this option is may also be potentiated (~70%) by PI therapy and available and is predicted to be virologically safe.
should be commenced at a low dosage initially (i.e. Current evidence also supports the use of lipid-10 mg/day). Pravastatin therapy does not appear to lowering therapy in these patients, irrespective of be affected by concomitant PI use. the severity of dyslipidaemia or the magnitude of response to lipid-lowering therapy, based on data
Management of Insulin Resistance and
from HIV-uninfected populations.
Diabetes Mellitus
In those patients whose risk is estimated at <20%, the situation is less clear-cut. In these cases, a review Experience with the management of diabetes in of the baseline metabolic profile of the patient can patients receiving HIV PI therapy is limited at this be informative.
time and no specific recommendations can be made 1. Normal lipid/lipoprotein parameters before PI in terms of treatment. The presence of diabetes therapy. In these patients, the benefits of lipid-low-confers an independent high risk of cardiovascular ering therapy are likely to be marginal, while non-disease and is likely to warrant statin therapy for this pharmacological approaches may have significant reason.
[134] This is also a situation in which PI therimpact in reducing metabolic complications. Reduc-apy should be avoided where possible. Otherwise, ing cardiovascular risk through attention to other the disease should be managed according to estabfactors (e.g. smoking, hypertension) is certainly lished guidelines. [146] warranted.
Studies of the pathophysiology of PI-associated 2. Abnormal lipid/lipoprotein parameters before PI metabolic complications suggest a rational basis for therapy. Patients with untreated HIV infection who the use of thiazolidinediones (rosiglitazone, pioghave elevated LDL cholesterol levels may have ge-litazone) as insulin-sensitising drugs in this setting. netically determined hypercholesterolaemia and The target of action of these drugs, PPAR-γ, lies in may require lipid-lowering therapy in addition to the transcriptional pathway that is normally stimulifestyle modification, particularly if there is a posi-lated by SREBP-1 and which appears to be defective tive family history of cardiovascular disease.
in the presence of PIs. In vitro, rosiglitazone has Otherwise, management should be guided by been shown to 'rescue' the adverse effects of PI currently available guidelines. However, an impor-therapy on insulin signalling, [87] and these drugs tant caveat is that lipid-lowering drugs are unlikely have also shown promise as therapeutic agents in to decrease cholesterol to 'goal' levels in patients cases of inherited lipodystrophy, which may also involve defects in the SREBP-1/PPAR-γ path-
The only caveat for metformin use is that weight loss associated with this drug may involve both way. [147] Limited data from small studies also sugsubcutaneous and visceral fat depots, so that lipoagest benefit in HIV-infected patients receiving PI trophy may worsen in patients with this complicatherapy. [148, 149] For example, in a study involving tion. For example, in the Boston study, [151] loss of eight subjects with significant insulin resistance at subcutaneous fat mass (~4.3% from baseline) was baseline (insulin sensitivity assessed using hyperincomparable with loss of visceral fat on CT scanning, sulinaemic-euglycaemic clamp [34% of age and so that the ratio of visceral fat to subcutaneous fat BMI-matched controls]), insulin sensitivity imremained unchanged (p = 0.71). Hence, this therapy proved by 59% after 6-12 weeks of rosiglitazone 8 appears to be ideal for patients who have insulin mg/day. The results of further large studies are resistance and visceral adiposity associated with awaited before this therapeutic approach can be HIV PI therapy, but who have been spared the recommended.
problem of lipoatrophy (which is predominantly Metformin has also been studied as an insulin NRTI associated). sensitising agent in two cohorts, both selected for the presence of insulin resistance and visceral/abdo-5. Conclusions minal obesity. The first study, performed by SaintMarc and Touraine [150] in France, involved 27 pa-
The use of PI therapy is independently associated tients with central obesity (average visceral adipose with dyslipidaemia and insulin resistance, and by implication to an increased risk of cardiovascular tissue area on CT scanning ~200 cm 2 ) and hyperindisease. However, there are a number of factors that sulinaemia in either the fasting or post-glucose state.
may modulate the severity of metabolic complicaRandomised therapy with metformin for 2 months at tions associated with this drug class. These include relatively high dose (n = 14, 850mg three times treatment-related factors (choice of PI therapy), host daily) was associated with significant improvements factors (e.g. diet and exercise status, presence of prein visceral adiposity compared with controls (deexisting metabolic syndromes) and disease-related crease of 37.5% vs gain of 10.4%, p < 0.01), as well factors (metabolic consequences of HIV infection as in fasting and post-glucose insulin levels (p < per se). Similarly, the global assessment of cardio-0.01 for both parameters). Metformin was generally vascular risk, which provides a guide to the use of well tolerated, with no reports of lactic acidosis, therapeutic interventions, such as lipid-lowering although two patients withdrew because of gastroin-therapy, incorporates a number of potentially moditestinal adverse effects (diarrhoea and abdominal fiable risk factors that require consideration along cramps). The second study, by Grinspoon and col-with the direct effects of PI therapy. Therefore, leagues [151] in Boston also selected patients with assessing, monitoring and managing the metabolic impaired glucose tolerance and/or fasting hyperin-complications of PI therapy requires an approach sulinaemia associated with central obesity, based on that is both individualised and holistic. a waist-hip ratio of >0.9 for men and >0.8 for Further elucidation of the pathophysiological women. Metformin therapy (n = 14, 500mg twice mechanisms underlying PI-associated metabolic daily) was compared with placebo over 3 months. complications, as a means of designing therapeutic Visceral fat mass also decreased, although non-interventions that are biologically rational, is awaitsignificantly, in this study (decrease of 6.3% vs gain ed with interest. It is also hoped that this 'natural of 7.7% in controls, p = 0.08), while post-glucose experiment', involving the use of therapy in patients insulin levels decreased by 20% among those on who are monitored by their physicians over prometformin (p = 0.01). Diarrhoea was common in longed periods, can provide insights into the pathothis study, affecting 69% of participants on metfor-genesis of other highly prevalent syndromes such as min, although there were no withdrawals.
the metabolic syndrome and diabetes. 
